Johnson & Johnson enters its October 13 Q3 2026 earnings release with an 84.5% market-implied probability of beating consensus estimates, supported by a consistent track record of outperformance and upwardly revised full-year guidance. The company delivered adjusted EPS of $2.90 in Q2 2026, exceeding the $2.85 consensus, alongside 6.6% reported sales growth to $25.31 billion, prompting management to lift 2026 targets to $101.1 billion in revenue and $11.68 in adjusted EPS. Momentum in oncology and immunology portfolios, including Darzalex, Carvykti, Tecvayli, Tremfya, and recent positive Phase 3 durability data for ICOTYDE in psoriasis, underpins operational strength. While in-process R&D charges may pressure GAAP results, adjusted metrics and sector-leading execution sustain trader consensus for another beat ahead of the release.